PD-L1 IHC 22C3 pharmDx is an assay that detects PD-L1 and is used to identify cancer patients eligible for pembrolizumab therapy. This E-course will give an overview of PD-L1 testing and the assay.

CPD Reviewer:

Professor Dr Pathmanathan Rajadurai

Senior Consultant Pathologist

Subang Jaya Medical Centre

Malaysia

Who should participate:

•             Oncologists

•             Pathologists

Learning objectives:

PD-L1 testing

•             To provide an overview of PD-1/ PD-L1 checkpoint inhibitors and the importance of PD-L1 testing

•             To discuss the challenges of PD-L1 testing and implications of using LDTs versus IVDs

•             To review the importance of personalised medicine and CDx

PD-L1 IHC 22C3 pharmDx assay

To provide an overview of PD-L1 IHC 22C3 pharmDx assay –

•             Assay overview

•             Scoring guidelines: TPS & CPS

•             Approved indications

•             Platforms: SK006 (Autostainer link) and GE006 (Dako Omnis)

•             Assay validation

Education & training resources

To provide guidance on –

•             Online education & training resources for using and interpreting PD-L1 IHC 22C3 pharmDx assay

•             External quality assurance programs for PD-L1 testing in laboratories

NOTE:

Please read thoroughly & understand the module before attempting the assessment questions.

Terms and Conditions:

•             Participants must obtain a minimum score of 8/10 (80%) to be awarded 1 point.

•             MIMS Education and MIMS Medica shall not be responsible or liable for the outcome of your CPD points.

Sponsored by:

Supported by: